Credit Suisse Upgrades Merck (MRK) to Outperform

August 8, 2016 6:22 AM EDT
Get Alerts MRK Hot Sheet
Price: $61.20 -1.16%

Rating Summary:
    13 Buy, 10 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MRK Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Credit Suisse upgraded Merck (NYSE: MRK) from Neutral to Outperform with a price target of $73.00 following news Friday that Bristol-Myers' CheckMate-026 (CM-026) Study for Opdivo in 1st line non-small cell lung cancer (NSCLC) missed its primary endpoint.

Analyst Vamil Divan commented, "Friday's developments help answer one of the main concerns we had on MRK as we struggled to see where they would find near to mid-term growth in the face of patent loss for Vytorin/Zetia, biosimilar competition for Remicade and increasing competition for Januvia/Janumet. Our MRK sales estimates increase by $1.6-$2.4 Bn for the next few years and our EPS estimates move to $4.06- $5.00 from $3.70-$4.45, suggesting a 2015-2019 EPS CAGR of 8.6%. Our DCF for MRK increases to $72. Our blended target price of 75% DCF/25% relative, with the relative based off of 18.0x our new 2017 EPS of $4.06, is $73. We acknowledge the lack of a CTLA-4 antibody could eventually limit MRK's potential in combination therapy. However, Keytruda will be a dominant player in monotherapy and MRK has quietly been developing a broad range of combination approaches as well."

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $63.86 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Upgrades

Related Entities

Credit Suisse

Add Your Comment